Man­u­fac­tur­ing roundup: Au­risco com­pletes FDA in­spec­tion of in­gre­di­ent pro­duc­tion site; NIH picks Exothera to de­vel­op nasal Covid vac­cine

Au­risco Phar­ma­ceu­ti­cal said Tues­day that the FDA gave it the green light to pro­duce ac­tive phar­ma­ceu­ti­cal in­gre­di­ents (APIs) at a man­u­fac­tur­ing site in Yangzhou, Chi­na.

The fa­cil­i­ty now has cGMP sta­tus and will pro­duce sev­er­al gener­ic APIs, in­clud­ing semaglu­tide, No­vo Nordisk’s block­buster type 2 di­a­betes and obe­si­ty drug, ac­cord­ing to a news re­lease.

The FDA con­duct­ed the in­spec­tion be­tween Aug. 7 and 11. No ob­ser­va­tions were found that war­rant­ed an in­spec­tion re­port.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER